GYRE Insider Trading Activity and SEC Form 4 Filings
GYRE insider trading summary
Over the past 12 months, insiders at Gyre Therapeutics, Inc. (GYRE) reported 16 sales worth $758K by 2 insiders and no open-market purchases on SEC Form 4. Net insider selling was $758K.
Latest GYRE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 18, 2026 | Weiguo Ye | Chief Operating Officer | Sell | $19K (3,000 @ $6.35) |
| Jun 11, 2026 | Weiguo Ye | Chief Operating Officer | Sell | $17K (2,800 @ $6.17) |
| Jun 10, 2026 | Weiguo Ye | Chief Operating Officer | Sell | $40K (6,418 @ $6.21) |
| Jun 10, 2026 | Weiguo Ye | Chief Operating Officer | Sell | $31K (5,000 @ $6.24) |
| Jun 9, 2026 | Weiguo Ye | Chief Operating Officer | Sell | $89K (14,500 @ $6.14) |
| Jun 9, 2026 | Weiguo Ye | Chief Operating Officer | Sell | $18K (3,000 @ $6.15) |
| Jun 5, 2026 | Weiguo Ye | Chief Operating Officer | Sell | $99K (15,401 @ $6.40) |
| Jun 4, 2026 | Weiguo Ye | Chief Operating Officer | Sell | $120K (19,575 @ $6.13) |
| May 26, 2026 | Weiguo Ye | Chief Operating Officer | Sell | $24K (4,000 @ $6.10) |
| May 22, 2026 | Weiguo Ye | Chief Operating Officer | Sell | $21K (3,500 @ $6.08) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.